Cargando…
Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study
PURPOSE: The aim of this study is to compare efficacy and toxicity between concurrent chemoradiotherapy (CCRT) followed by high-dose-rate intraluminal brachytherapy (ILBT) and CCRT in inoperable, locally advanced esophageal carcinoma. MATERIAL AND METHODS: Thirty-four patients with inoperable, local...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052387/ https://www.ncbi.nlm.nih.gov/pubmed/30038642 http://dx.doi.org/10.5114/jcb.2018.76843 |
_version_ | 1783340644368908288 |
---|---|
author | Halder, Anirban Biswas, Rituparna Ghosh, Anshuman Dastidar, Aloke Ghosh |
author_facet | Halder, Anirban Biswas, Rituparna Ghosh, Anshuman Dastidar, Aloke Ghosh |
author_sort | Halder, Anirban |
collection | PubMed |
description | PURPOSE: The aim of this study is to compare efficacy and toxicity between concurrent chemoradiotherapy (CCRT) followed by high-dose-rate intraluminal brachytherapy (ILBT) and CCRT in inoperable, locally advanced esophageal carcinoma. MATERIAL AND METHODS: Thirty-four patients with inoperable, locally advanced esophageal carcinoma were randomized into two arms. In the CCRT + ILBT arm (arm A), eighteen patients received 50.4 Gy at 1.8 Gy per fraction over 5.6 weeks, along with concurrent cisplatin (75 mg/m(2)) intravenously on day 1, and 5-fluorouracil (1000 mg/m(2)) continuous intravenous infusion on days 1-5, starting on the first day of irradiation and repeated after 28 days. This was followed by ILBT boost with a dose of 10 Gy in 2 fractions, one week apart. In the CCRT arm (arm B), sixteen patients received two cycles of chemotherapy, using the same schedule, along with external beam radiotherapy fractionated in a similar manner without brachytherapy boost. The endpoints were tumor response, acute and late toxicities, disease and progression-free survival. RESULTS: With a median follow-up of 13 months, the complete response rate was 88.89% in arm A and 87.50% in arm B (p = 0.71). Acute esophageal toxicity was higher in CCRT followed by ILBT arm (p = 0.60). There was no significant difference between the Kaplan Meier survival plots of disease-free survival (p = 0.68) and progression-free survival (p = 0.55). CONCLUSIONS: In our study, addition of brachytherapy as a boost following concurrent chemoradiation failed to improve treatment outcomes without additional toxicity in locally advanced esophageal cancer. |
format | Online Article Text |
id | pubmed-6052387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-60523872018-07-23 Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study Halder, Anirban Biswas, Rituparna Ghosh, Anshuman Dastidar, Aloke Ghosh J Contemp Brachytherapy Original Paper PURPOSE: The aim of this study is to compare efficacy and toxicity between concurrent chemoradiotherapy (CCRT) followed by high-dose-rate intraluminal brachytherapy (ILBT) and CCRT in inoperable, locally advanced esophageal carcinoma. MATERIAL AND METHODS: Thirty-four patients with inoperable, locally advanced esophageal carcinoma were randomized into two arms. In the CCRT + ILBT arm (arm A), eighteen patients received 50.4 Gy at 1.8 Gy per fraction over 5.6 weeks, along with concurrent cisplatin (75 mg/m(2)) intravenously on day 1, and 5-fluorouracil (1000 mg/m(2)) continuous intravenous infusion on days 1-5, starting on the first day of irradiation and repeated after 28 days. This was followed by ILBT boost with a dose of 10 Gy in 2 fractions, one week apart. In the CCRT arm (arm B), sixteen patients received two cycles of chemotherapy, using the same schedule, along with external beam radiotherapy fractionated in a similar manner without brachytherapy boost. The endpoints were tumor response, acute and late toxicities, disease and progression-free survival. RESULTS: With a median follow-up of 13 months, the complete response rate was 88.89% in arm A and 87.50% in arm B (p = 0.71). Acute esophageal toxicity was higher in CCRT followed by ILBT arm (p = 0.60). There was no significant difference between the Kaplan Meier survival plots of disease-free survival (p = 0.68) and progression-free survival (p = 0.55). CONCLUSIONS: In our study, addition of brachytherapy as a boost following concurrent chemoradiation failed to improve treatment outcomes without additional toxicity in locally advanced esophageal cancer. Termedia Publishing House 2018-06-29 2018-06 /pmc/articles/PMC6052387/ /pubmed/30038642 http://dx.doi.org/10.5114/jcb.2018.76843 Text en Copyright: © 2018 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Halder, Anirban Biswas, Rituparna Ghosh, Anshuman Dastidar, Aloke Ghosh Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study |
title | Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study |
title_full | Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study |
title_fullStr | Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study |
title_full_unstemmed | Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study |
title_short | Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study |
title_sort | comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052387/ https://www.ncbi.nlm.nih.gov/pubmed/30038642 http://dx.doi.org/10.5114/jcb.2018.76843 |
work_keys_str_mv | AT halderanirban comparativestudyofconcomitantchemoradiationversusconcomitantchemoradiationfollowedbyhighdoserateintraluminalbrachytherapyinlocallyadvancedesophagealcarcinomaasingleinstitutionalstudy AT biswasrituparna comparativestudyofconcomitantchemoradiationversusconcomitantchemoradiationfollowedbyhighdoserateintraluminalbrachytherapyinlocallyadvancedesophagealcarcinomaasingleinstitutionalstudy AT ghoshanshuman comparativestudyofconcomitantchemoradiationversusconcomitantchemoradiationfollowedbyhighdoserateintraluminalbrachytherapyinlocallyadvancedesophagealcarcinomaasingleinstitutionalstudy AT dastidaralokeghosh comparativestudyofconcomitantchemoradiationversusconcomitantchemoradiationfollowedbyhighdoserateintraluminalbrachytherapyinlocallyadvancedesophagealcarcinomaasingleinstitutionalstudy |